Skip to main content
. 2020 Jan 14;26(2):199–218. doi: 10.3748/wjg.v26.i2.199

Figure 2.

Figure 2

Gray’s test showed that the cumulative survival was significantly higher in the rifaximin group than in the control group. aP < 0.05 vs control group.